NuPulseCV

NuPulseCV is a clinical-stage medical device company pioneering a novel approach to mechanical circulatory support for chronic heart failure patients. Its flagship product, the NuPulse Voyage, is a minimally invasive, portable system that utilizes counterpulsation technology, aiming to serve as a bridge-to-transplant or destination therapy while enabling patient mobility and discharge. Founded in 2015 and based in Durham, NC, the company has completed an 81-patient early feasibility study with promising results and is now advancing toward a pivotal trial. NuPulseCV seeks to address a significant gap in long-term, ambulatory cardiac support for a large and growing patient population.

Minimally invasive cardiac assist device based on counterpulsation physiology, featuring a portable drive unit and percutaneous implant.

NuPulseCV competes in the mechanical circulatory support market against dominant players like Abbott (HeartMate 3) and Medtronic. Its primary differentiation is a less invasive implant and a portable system designed for discharge, targeting chronic heart failure rather than acute cardiogenic shock. It faces competition from other novel, minimally invasive devices in development.